Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent therapeutic activity of LNAplus™ ASO targeting NLRP3 in debilitating autoinflammatory diseases – Biotech Investments
EQS-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication Secarna Pharmaceuticals publishes new preclinical data in The Journal of Immunology demonstrating potent